Nefiracetam hydroxylation by rat liver microsomes and expressed human cytochrome P450s

References

• Boobis A. R., Sesardic D., Murray B. P., Edwards R. J., Singleton A. M., Rich K. J., Murray S., De La Torre R., Segura J., Pelkonen O., Pasanen M., Kabayashi S., Zhi-Guang T., Davis D. S. Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 1990; 20: 1139–1161
   PubMed Web of Science ®Google Scholar
• Bork R. W., Muto T., Beaune P. H., Srivastava P. K., Lloyd R. S., Guengerich F. P. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the reguration of catalytic activity. Journal of Biological Chemistry 1989; 264: 910–919
   PubMed Web of Science ®Google Scholar
• Dixon M., Webb E. C. Enzyme inhibitors. Enzymes 1972; 315–359
   Google Scholar
• Fujimaki Y., Hashimoto K., Sudo K., Tachizawa H. Biotransformation of a new pyrrolidinone cognition-enhancing agent: isolation and identification of metabolites in human urine. Xenobiotica 1990; 20: 1081–1094
   PubMed Web of Science ®Google Scholar
• Fujimaki Y., Sudo K., Hakusui H. Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. Xenobiotica 1993; 23: 61–70
   PubMed Web of Science ®Google Scholar
• Fujimaki Y., Sudo K., Hakusui H. In vitro metabolism of nefiracetam by liver microsomes from rats, dogs and monkeys. Arzneimittelforschung 1995; 45: 748–752
   PubMed Web of Science ®Google Scholar
• Gibson G. G., Orton T. C., Tamburini P. P. Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). Biochemical Journal 1982; 203: 161–168
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacological Review 1988; 40: 243–288
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. Human cytochromes P450: problems and prospects. Trends in Pharmacological Science 1992; 13: 346–352
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T., Waxman D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1986; 261: 5051–5060
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Enzymology of rat liver cytochrome P-450. Mammalian Cytochromes P-450, F. P. Guengerich. CRC Press, Inc., Boca Raton, Florida 1987; Vol. 1: 1–54
   Google Scholar
• Henderson C. J., Wolf C. R. Molecular analysis of cytochrome P450s in the CYP2 gene family. Progressing in Drug Metabolism 1992; 13: 73–139
   Google Scholar
• Kameyama T., Nabeshima T., Tohyama K., Ogawa S., Murase K., Ishihara S. DM-9384, a pyrrolidone derivative, ameliorates basal forebrain (BF) lesion-induced amnesia and inhibits cycloheximide (CXM)-induced decrease of GABA and acetylcholine (ACh) receptors. Advances in Behavioral Biology, T. Nagatsu, A. Fisher, M. Yoshida. Plenum Press, New York & London 1990; Vol. 38B: 371–374
   Google Scholar
• Kawajiri S., Taniguchi K., Sakurai T., Kojima H., Yamazaki T. Effect of DM-9384 on extracellular acetylcholine in the rat frontal cortex measured with microdialysis. European Journal of Pharmacology 1990; 183: 928
   Web of Science ®Google Scholar
• Kojima H., Kawajiri S., Sakurai T., Yamasaki T. Effect of DM-9384, a new pyrrolidone derivative, on passive avoidance and cerebral choline acetyltransferase activity in rats. Advances in Behavior al Biology, T. Nagatsu, A. Fisher, M. Yoshida. Plenum Press, New York & London 1990; Vol. 38B: 367–370
   Google Scholar
• Komori M., Nishino K., Kitada M., Shiramatsu K., Muroya K., Soma M., Nagashima K., Kamataki T. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 1990; 29: 4430–4433
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Nabeshima T., Yohyama K., Kameyama T. Effects of DM-9384, a pyrrolidone derivative, on alcohol- and chlordiazepoxide-induced amnesia in mice. Pharmacology Biochemistry & Behavior 1990a; 36: 233–236
   PubMed Web of Science ®Google Scholar
• Nabeshima T., Tohyama K., Murase K., Ishihara S., Kameyama T., Yamasaki T., Hatanaka S., Kojima H. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunction. European Journal of Pharmacology 1990b; 178: 143–149
   PubMed Web of Science ®Google Scholar
• Nabeshima T., Tohyama K., Murase K., Ishihara S., Kameyama T., Yamasaki T., Hatanaka S., Kojima H. Effects of DM-9384, a cyclic derivative of GABA, on cycloheximide-induced amnesia and GABAergic & cholinergic neuronal dysfunction. Journal of Pharmacology and Experimental Therapeutics 1991; 257: 271–275
   PubMed Web of Science ®Google Scholar
• Parke D. V. Induction of cytochromes P-450. General principles and biological consequences. Frontiers in Biotransformation, K. Ruckpaul, H. Rein. Taylor & Francis, London 1990; Vol. 2: 2–28
   Google Scholar
• Peter R., Bocker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology 1990; 3: 566–573
   PubMed Web of Science ®Google Scholar
• Porter T. D., Coon M. J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. Journal of Biological Chemistry 1991; 266: 13469–13472
   PubMed Web of Science ®Google Scholar
• Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich P. F. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasions. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Sudo K., Hashimoto K., Fujimaki Y., Tachizawa H. Disposition and metabolism of Nefiracetam, a New Nootropic Agent, in the rat, dog and monkey. Japanese Pharmacology & Therapeutics 1994; 22: 3441–3452
   Google Scholar
• Watabe S., Yamaguchi H., Ashida S. Effects of DM-9384, a new cognition-enhancing agent, on GABA release and choline uptake in rat cortex. Proceedings of the 19th Annual Meeting of Society for Neuroscience. 1989, 601, 15
   Google Scholar
• Waxman D. J., Walsh C. Phenobarbital-induced rat liver cytochrome P-450. Journal of Biological Chemistry 1982; 257: 10446–10457
   PubMed Web of Science ®Google Scholar
• Waxman D. J. Rat hepatic cytochrome P-450. Cytochrome P-450, P. R. Otiz de Montellano. Plenum Press, New York 1986; 525–539
   Google Scholar
• Yamaoka K., Tanigawa Y., Nakagawa N., Uno T. A Pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics 1981; 4: 879–885
   PubMedGoogle Scholar
• Yang C. S., Patten C. J., Ishizaki H., Yoo H. J.-S. Induction, purification, and characterization of cytochrome P-450IIE. Methods in Enzymology, M. R. Waterman, E. F. Johnson. Academic Press, INC., San Diego 1991; Vol. 206: 595–603
   Google Scholar
• Yoshii M., Watabe S., Murashima Y., Nakamoto Y., Shiotani T., Tanaka M., Tachizawa H. Facilitation of long-lasting (type-II) Ca++ channel currents by a cognitive enhancer DM-9384 requires a phosphorylation process in NG108–15 cells. Proceedings of the 21th Annual Meeting of Society for Neuroscience. 1991, 774, 17
   Google Scholar
• Yoshii M., Watabe S., Murashima Y., Nakamoto Y., Shiotani T., Tanaka M. Site of action of cognitive enhancer DM-9384 that enhances long-lasting calcium channel currents in NG108–15 cells. Proceedings of the 22th Annual Meeting of Society for Neuroscience. 1992, 435, 18
   Google Scholar